ARK Invest Sells Shares, 10x Genomics Stock Price Plummets

LootboxPhobia · 2026-03-17T04:44:10+00:00

10x Genomics stock price dropped 12% following ARK Invest's sale of 473,000 shares. The company's reallocation of investments in genomics tools toward gene editing platforms has triggered market concerns and may lead to selloffs by other institutions. With muted 2026 revenue forecasts, investors are taking a cautious stance on 10x Genomics' growth prospects.

LootboxPhobia

2026-03-17 04:44:10

Abstract generation in progress

Investing.com – 10x Genomics (NASDAQ:TXG) stock dropped 12% after ARK Invest sold over 473,000 shares in its flagship exchange-traded fund, marking a significant shift in the company’s positioning toward this genomics tools manufacturer.

The sell-off by Cathie Wood’s investment firm has raised market concerns that other institutional investors may also reduce their holdings, putting pressure on the stock. ARK Invest has been reallocating funds from genomics tools manufacturers to gene editing platforms.

This sale comes at a time when investors are cautious about 10x Genomics’ growth prospects. The company’s previously issued revenue growth guidance for 2026 was modest, which has put pressure on market expectations for the stock.

10x Genomics develops instruments and software for analyzing biological systems at single-cell resolution. The company serves researchers in oncology, immunology, and neuroscience.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes